{"id":"hearticellgram-ami","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL518352","moleculeType":"Small molecule","molecularWeight":"519.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of patient's own bone marrow cells that are processed and administered to damaged myocardial tissue to stimulate neovascularization, reduce inflammation, and promote functional recovery of the heart. This cell-based approach aims to restore cardiac function by leveraging the regenerative and paracrine properties of bone marrow cells in the post-infarction setting.","oneSentence":"Hearticellgram-AMI is an autologous bone marrow-derived cell therapy that promotes cardiac regeneration and repair following acute myocardial infarction.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:58.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction with reduced left ventricular ejection fraction"}]},"trialDetails":[{"nctId":"NCT07400458","phase":"NA","title":"Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration","status":"RECRUITING","sponsor":"Pharmicell Co., Ltd.","startDate":"2022-03-03","conditions":"Acute Myocardial Infarction","enrollment":100},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":"Acute Myocardial Infarction","enrollment":90},{"nctId":"NCT01595113","phase":"","title":"Safety Study of Clinical Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2012-05","conditions":"Acute Myocardial Infarction","enrollment":41},{"nctId":"NCT01392105","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2007-03","conditions":"Acute Myocardial Infarction","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(Autologous bone marrow derived mesenchymal stem cells)"],"phase":"phase_3","status":"active","brandName":"Hearticellgram-AMI","genericName":"Hearticellgram-AMI","companyName":"Pharmicell Co., Ltd.","companyId":"pharmicell-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hearticellgram-AMI is an autologous bone marrow-derived cell therapy that promotes cardiac regeneration and repair following acute myocardial infarction. Used for Acute myocardial infarction with reduced left ventricular ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}